Van Lanschot Kempen Logo
  • Home
  • Solutions
  • News & knowledge
  • About us
Nov 2016
biocartis
Joint bookrunner
€ 32.6 million

Biocartis

Biocartis is an innovative commercial stage molecular diagnostics company providing next generation diagnostic solutions.

  • Accelerated bookbuild offering amounting to €32.7m.
  • Proceeds will be used to finance further clinical trials, to support the global roll-out of its products and to fund the expansion of manufacturing capacity. 
  • Kempen & Co acted as Joint Bookrunner in the transaction.
     

Fully focused on your future

Private Banking

  • Offices
  • Business professionals
  • Executives
  • Doctors
  • Entrepreneurs
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions


Investment Management


Investment Banking



© Van Lanschot Kempen 2022
Security
Privacy & cookies
Disclaimer